Bouchereau, Sarah
Chaplain, Louise
Fort, Magali
Beauchet, Alain
Sidibé, Thomas
Chapalain, Marie
Gonzalez-Lara, Leire
Longvert, Christine
Blom, Astrid
Saiag, Philippe
Funck-Brentano, Elisa http://orcid.org/0000-0002-1092-0789
Article History
Received: 14 March 2021
Revised: 7 June 2021
Accepted: 1 July 2021
First Online: 14 July 2021
Ethics approval and consent to participate
: According to French Law, this study abided by standard medical practices and did not require a written informed consent. However, consent was obtained orally from all patients. In addition, patients gave written informed consent to participate in national French prospective cohorts of advanced melanoma (MelBase: NTC028228202, RIC-Mel: NCT03315468, MelanCohort). The study was conducted according to the principles of the declaration of Helsinki.
: CL: Pierre Fabre, Novartis, Bristol-Myers Squibb and MSD (C/A). PS: Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, and Novartis (C/A). EFB: Pierre Fabre, Novartis, Bristol-Myers Squibb and MSD (C/A). (C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.Authors’ information (optional).
Free to read: This content has been made available to all.